Oral lichenoid reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings

Journal of the European Academy of Dermatology and Venereology

Volumn 31, Issue 10, 2017, Pages e464-e469

  Sibaud, V ^a   Eid, C ^b   Belum, V R ^c   Combemale, P ^d   Barres, B ^a   Lamant, L ^a   Mourey, L ^a   Gomez Roca, C ^a   Estilo, C L ^c   Motzer, R ^c   Vigarios, E ^a   Lacouture, M E ^c  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; CLOBETASOL; DEXAMETHASONE; NIVOLUMAB; PEMBROLIZUMAB; PREDNISOLONE; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR;

ADVANCED CANCER; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LETTER; LICHENOID; ORAL LICHENOID REACTION; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; XEROSTOMIA; ADULT; AGED; ANTAGONISTS AND INHIBITORS; CASE REPORT; CHEMICALLY INDUCED; FEMALE; LICHENOID ERUPTION; MALE; MIDDLE AGED; MOUTH DISEASE; NEOPLASM; PATHOLOGY;

ADULT; AGED; FEMALE; HUMANS; LICHENOID ERUPTIONS; MALE; MIDDLE AGED; MOUTH DISEASES; NEOPLASMS; PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85019111398     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.14284     Document Type: Letter

References (10)

1. Sibaud V, Meyer N, Lamant L et al. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol 2016; 28: 254–263.
2. Belum VR, Benhuri B, Postow MA et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 2016; 60: 12–25.
3. Bonigen J, Raynaud-Donzel C, Hureaux J et al. Anti-PD1-induced psoriasis. A study of 21 patients. J Eur Acad Dermatol Venereol 2017; 31: e254–e257.
4. Hofmann L, Forschner A, Loquai C et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 2016; 60: 190–209.
5. Schaberg KB, Novoa RA, Wakelee HA et al. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. J Cutan Pathol 2016; 43: 339–346.
6. Shi VJ, Rodic N, Gettinger S et al. Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death Ligand 1 immunotherapy. JAMA Dermatol 2016; 152: 1128–1136.
7. Hwang SJ, Carlos G, Wakade D et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. J Am Acad Dermatol 2016; 74: 455–461.
8. Chou S, Hwang SJ, Carlos G et al. Histologic assessment of lichenoid dermatitis observed in patients with advanced malignancies on antiprogramed cell death-1 (anti-PD-1) therapy with or without ipilimumab. Am J Dermatopathol 2017; 39: 23–27.
9. Zhou G, Zhang J, Ren XW et al. Increased B7-H1 expression on peripheral blood T cells in oral lichen planus correlated with disease severity. J Clin Immunol 2012; 32: 794–801.
10. Vigarios E, Epstein JB, Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer 2017;25: 1713–1739.